Although many tumor markers have been identified and studied in epithelial ovarian cancer,a potential and useful screening marker for ovarian cancer has not been yet clearly established.Ovarian cancer is considered as a "silent killer" because of the absence of specific symptoms until late stage. Several validated biomarkers are currently used to diagnose and monitor the progression of the cancer, but very few of them show adequate specificity and sensitivity for different population screening.There is therefore an urge need to find biomarkers with high diagnostic accuracy and set up screening programs which can help detect ovarian cancer early, predict the response of the patient to anticancer therapy and guide physicians in choosing the best treatment for the patient.CA125,HE4 and STIP1 have been proven to play an important role as biomarkers in detecting and monitoring ovarian cancer.In this paper,we review evaluate,and highlight the role of CA125,HE4 and STIP1 in the detection of ovarian cancer. Potential biomarkers can help us distinguish malignancy from benign pelvic mass.

[1] PFISTERER J,HARTER P,SIMONELLI C,et al.Abagovomab for ovarian cancer[J].Expert Opin Biol Ther,2011,11(3):395-403.
[2] SCHORGE J O,McCANN C,del CARMEN M G.Surgical debulking of ovarian cancer:what difference does it make？[J].Rev Obstet Gynecol,2010,3(3):111-117.
[3] BAST R C,FEENEY M,LAZARUS H,et al.Reactivity of a monoclonal antibody with human ovarian carcinoma[J].J Clin Invest,1981,68,1331-1337.
[4] STURGEON C M,DUFFY M J,STENMAN U H,et al.National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in testicular,prostate,colorectal,breast,and ovarian cancers[J].Clin Chem,2008,54(12):e11-79.
[5] ESCUDERO J M,AUGE J M,FILELLA X,et al.Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases[J].Clin Chem,2011,57:1534-1544.
[6] BAST R C,BADGWELL D,LU Z,et al.New tumor markers:CA125 and beyond[J].Int Gynecol Cancer,2005,15:274-281.
[7] PARTHA M D,ROBERT C B Jr.Early detection of ovarian cancer[J].Biomark Med,2008,2(3):291-303.
[8] HGDALL E V,CHRISTENSEN L,KJAER S K,et al.CA125 expression pattern,prognosis and correlation with serum CA125 in ovarian tumor patients.From the Danish "MALOVA" Ovarian Cancer Study[J].Gynecol Oncol,2007,104(3):508-515.
[9] KIRCHOFF C,HABBEN I,IVELL R,et al.A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors[J].Biol Reprod,1991,45:350-357.
[10] JIANG S W,CHEN H,DOWDY S,et al.HE4 transcription-and splice variants-specific expression in endometrial cancer and correlation with patient survival[J].Int J Mol Sci,2013,14(11):22655-22677.
[11] MONTAGNANA M,DANESE E,RUZZENENTE O,et al.The ROMA(risk of ovarian malignancy algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass:is it really useful？[J].Clin Chem Lab Med,2011,49:521-525.
[12] HELLSTROM I,HELLSTROM K E.SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other[J].Ovarian Cancer,2008,622:15-21.
[13] ANGIOLI R,MIRANDA A,ALOISI A,et al.A critical review on HE4 performance in endometrial cancer:where are we now？[J].Tumour Biol,2014,35(2):881-887.
[14] BOLSTAD N,IJORDSBAKKEN M,NUSTAD K,et al.Human epididymis protein 4 reference limits and natural variation in a Nordic reference population[J].Tumour Biol,2012,33(1):141-148.
[15] ANASTASI E,MARCHEI G G,VIGGIANI V,et al.HE4:a new potential early biomarker for the recurrence of ovarian cancer[J].Tum Biol,2010,31,113-119.
[16] LI J,DOWDY S,TIPTON T,et al.HE4 as a biomarker for ovarian and endometrial cancer management[J].Expert Rev Mol Diagn,2009,9(6):555-566.
[17] LIU W,YANG J,CHI P D,et al.Evaluating the clinical significance of serum HE4 levels in lung cancer and pulmonary tuberculosis[J].Int J Tuberc Lung Dis,2013,17(10):1346-1353.
[18] BINGLE L,SINGLETON V,BINGLE C D,et al.The putative ovarian tumour marker gene HE4(WFDC2),is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms[J].Oncogene,2002,21(17):2768-2773.
[19] MOKHTAR N,THEVARAJAH M,MA N,et al.Human epididymis protein 4 reference intervals in a multiethnic Asian women population[J].Asian Pac Cancer Prev,2012,13(12):6391-6395.
[20] PITTA D R,SARIAN L O,BARRETA A,et al.Symptoms,CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses[J].BMC Cancer,2013,13:423.
[21] CHAO A,LAI C H,TSAI C L,et al.Tumor stress-induced phosphoprotein1(STIP1)as a prognostic biomarker in ovarian cancer[J].PLoS One,2013,8(2):e57084.
[22] SCHMID A B,LAGLEDER S,GRWERT M A,et al.The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop[J].EMBO J,2012,31(6):1506-1517.
[23] ODUNUGA O O,LONGSHAW V M,BLATCH G L,et al.Hop:more than an Hsp70/Hsp90 adaptor protein[J].Bioessays,2004,26(10):1058-1068.
[24] TSAI C L,TSAI C N,LIN C Y.Secreted stress-induced phosphoprotein 1 activates the ALK2-SMAD signaling pathways and promotes cell proliferation of ovarian cancer cells[J].Cell Rep,2012,2(2):283-293.
[25] WANG T H,CHAO A,TSAI C L,et al.Stress-induced phosphoprotein 1 as a secreted biomarker for human ovarian cancer promotes cancer cell proliferation[J].Mol Cell Proteomics,2010,9(9):1873-1884.
[26] FERRARO S,BRAGA F,LANZONI M,et al.Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis[J].Clin Pathol,2013,66(4):273-281.
[27] CHARPIN C,BHAN A K,ZURAWSKI V R,et al.Carcinoembryonic antigen(CEA)and carbohydrate determinant 19-9(CA 19-9)localization in 121 primary and metastatic ovarian tumors:an immunohistochemical study with the use of monoclonal antibodies[J].Int J Gynecol Pathol,1982,1(3):231.
[28] RAMA M,KAISER J.Specificity of serum tumor markers(CA125,CEA,AFP,Beta HCG)in ovarian malignancies[J].Trends Med Res,2007,2:128-134.
[29] MOORE R,JABRE-RAUGHLEY G,AMY K,et al.Comparison of a novel multiple marker assay versus the risk of malignancy index for the prediction of epithelial ovarian cancer in patients with a pelvic mass[J].Am J Obstet Gynecol,2010,203(3):228.
[30] KOBAYASHI E,UEDA Y.Biomarkers for screening,diagnosis,and monitoring of ovarian cancer[J].Cancer Epidemiol Biomarkers Prev,2012,21:1902-1912.
[31] KIM Y M,WHANG D H,PARK J,et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer:a prospective case-control study in a Korean population[J].Clin Chem Lab Med,2011,49:527-534.
[32] BERGMANN J F,BEAUGRAND M,LABADIE H,et al.CA 125(ovarian tumour-associated antigen)in ascitic liver diseases[J].Clin Chim Acta,1986,155(2):163-165.
[33] BREITENECKER G,NEUNTEUFEL W,BIEGLMAYER C,et al.Comparison between tissue and serum content of CA 125,CA 19-9 and carcinoembryonic antigen in ovarian tumours[J].Int J Gynecol Pathol,1989,8:97-102.